Plaintiffs Fight Privilege Claim In Neurontin Case

Law360, New York (February 22, 2010, 2:13 PM EST) -- Direct purchaser plaintiffs accusing Pfizer Inc. and a subsidiary of blocking generic competition for the epilepsy drug Neurontin by filing baseless patent litigation want a federal judge to look for evidence of crime or fraud in documents allegedly covered by attorney-client privilege.

Louisiana Wholesale Drug Co. Inc. and Meijer Inc. filed their motion for discovery pursuant to the crime-fraud exception in the U.S. District Court for the District of New Jersey on Friday.

The plaintiffs said they have put forth a "sufficient and good faith basis"...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.